Merck’s sacituzumab tirumotecan (sac-TMT) cleared a major late-stage hurdle in advanced endometrial cancer, becoming the first TROP2 antibody–drug conjugate to show an overall survival and progression-free survival benefit in a global Phase III trial, the company reported. The result positions sac-TMT as a new treatment option ahead of established ADC targets in the indication. The Phase III readout expands Merck’s women’s oncology push for an ADC strategy that has increasingly focused on survival endpoints after prior studies emphasized response metrics. Analysts will now look at how the win shapes positioning versus other ADCs under investigation in endometrial disease. Separate pipeline context: the same industry update noted investor pullback around late-stage readouts across other programs, underscoring how endpoint clarity continues to move markets in ADC-driven oncology development.